Ocugen, Inc. (OCGN)
0.8278
-0.05
(-5.24%)
USD |
NASDAQ |
Nov 13, 16:00
0.8278
0.00 (0.00%)
After-Hours: 19:59
Ocugen Enterprise Value : 285.18M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 285.18M |
| November 12, 2026 | 300.72M |
| November 11, 2026 | 330.18M |
| November 10, 2026 | 326.65M |
| November 09, 2026 | 334.14M |
| November 06, 2026 | 318.16M |
| November 05, 2026 | 281.35M |
| November 04, 2026 | 301.03M |
| November 03, 2026 | 257.16M |
| November 02, 2026 | 250.20M |
| October 30, 2026 | 242.74M |
| October 29, 2026 | 256.82M |
| October 28, 2026 | 267.74M |
| October 27, 2026 | 261.30M |
| October 26, 2026 | 244.67M |
| October 23, 2026 | 255.29M |
| October 22, 2026 | 272.36M |
| October 21, 2026 | 280.87M |
| October 20, 2026 | 279.99M |
| October 19, 2026 | 271.44M |
| October 16, 2026 | 269.07M |
| October 15, 2026 | 280.40M |
| October 14, 2026 | 289.73M |
| October 13, 2026 | 304.73M |
| October 12, 2026 | 325.70M |
| Date | Value |
|---|---|
| October 09, 2026 | 328.51M |
| October 08, 2026 | 335.94M |
| October 07, 2026 | 343.61M |
| October 06, 2026 | 357.18M |
| October 05, 2026 | 357.18M |
| October 02, 2026 | 350.40M |
| October 01, 2026 | 343.61M |
| September 30, 2026 | 353.79M |
| September 29, 2026 | 357.49M |
| September 28, 2026 | 337.15M |
| September 25, 2026 | 333.76M |
| September 24, 2026 | 326.98M |
| September 23, 2026 | 326.98M |
| September 22, 2026 | 340.54M |
| September 21, 2026 | 337.15M |
| September 18, 2026 | 347.32M |
| September 17, 2026 | 337.15M |
| September 16, 2026 | 326.44M |
| September 15, 2026 | 324.78M |
| September 14, 2026 | 347.32M |
| September 11, 2026 | 333.76M |
| September 10, 2026 | 335.46M |
| September 09, 2026 | 349.02M |
| September 08, 2026 | 438.86M |
| September 04, 2026 | 449.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 160.67M |
| Nektar Therapeutics | 789.44M |
| Heron Therapeutics, Inc. | 168.30M |
| TG Therapeutics, Inc. | 10.00B |
| Tonix Pharmaceuticals Holding Corp. | -103.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.598M |
| Revenue (Quarterly) | 1.951M |
| Total Expenses (Quarterly) | 5.549M |
| EPS Diluted (Quarterly) | -0.0106 |
| Gross Profit Margin (Quarterly) | 71.91% |
| Profit Margin (Quarterly) | -184.4% |
| Earnings Yield | -24.08% |
| Normalized Earnings Yield | -27.13 |